Literature DB >> 16026323

Role for poly(ADP-ribose) polymerase activation in diabetic nephropathy, neuropathy and retinopathy.

Irina G Obrosova1, Ulrich A Julius.   

Abstract

Chronic complications of diabetes mellitus e.a. diabetic nephropathy, neuropathy and retinopathy develop in at least 30-50% of patients with both Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetes, and are the major cause of increased morbidity and mortality. The ultimate consequences of diabetes complications include renal failure, foot ulceration and amputation, and blindness. The magnitude of the problem and its economic impact make extremely important to understand the natural history of chronic diabetes complications and to identify more successful preventive and therapeutic options. The pathogenesis of diabetes complications involves multiple mechanisms. The importance of vascular component is well recognized in diabetic retinopathy, which is primarily a vascular disease, as well as diabetic nephropathy developing as a result of complex interplay between hemodynamic and metabolic factors. The importance of vascular versus non-vascular mechanisms in the pathogenesis of diabetic neuropathy remains a subject of debate. Studies in animal and cell culture models revealed that such mechanisms as increased aldose reductase activity, non-enzymatic glycation/glycoxidation, activation of protein kinase C, impaired growth factor support, enhanced oxidative/nitrosative stress, and its downstream effectors such as mitogen-activated protein kinase activation, inflammatory response, endothelin-1 overexpression and impaired Ca(++) signaling, play an important role in all three tissue-targets for diabetes complications i.e. kidney, retina and peripheral nerve. Evidence for important role of the downstream effector of free radical and oxidant-induced DNA injury, poly(ADP-ribose) polymerase activation, is emerging. This review describes recent studies addressing the role for poly(ADP-ribose) polymerase activation in diabetic nephropathy, neuropathy and retinopathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16026323     DOI: 10.2174/1570161054368634

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  25 in total

Review 1.  Modulation of diabetic retinopathy pathophysiology by natural medicines through PPAR-γ-related pharmacology.

Authors:  Min K Song; Basil D Roufogalis; Tom H W Huang
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

2.  Modulation of neuropathic pain in experimental diabetes mellitus.

Authors:  Laurentiu Bădescu; Oana Bădulescu; Manuela Ciocoiu; Magda Bădescu
Journal:  J Physiol Biochem       Date:  2014-01-14       Impact factor: 4.158

Review 3.  Pathophysiological Role of Peroxynitrite Induced DNA Damage in Human Diseases: A Special Focus on Poly(ADP-ribose) Polymerase (PARP).

Authors:  Badar Ul Islam; Safia Habib; Parvez Ahmad; Shaziya Allarakha; Asif Ali
Journal:  Indian J Clin Biochem       Date:  2015-01-20

4.  Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption.

Authors:  Mohanraj Rajesh; Partha Mukhopadhyay; Sándor Bátkai; György Haskó; Lucas Liaudet; Viktor R Drel; Irina G Obrosova; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-03-23       Impact factor: 4.733

Review 5.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 6.  Mechanisms of disease: the oxidative stress theory of diabetic neuropathy.

Authors:  Claudia Figueroa-Romero; Mahdieh Sadidi; Eva L Feldman
Journal:  Rev Endocr Metab Disord       Date:  2008-12       Impact factor: 6.514

7.  SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy.

Authors:  Andrea M Vincent; James W Russell; Kelli A Sullivan; Carey Backus; John M Hayes; Lisa L McLean; Eva L Feldman
Journal:  Exp Neurol       Date:  2007-08-03       Impact factor: 5.330

Review 8.  Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease.

Authors:  Pal Pacher; Csaba Szabo
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

Review 9.  Diabetic neuropathy: mechanisms to management.

Authors:  James L Edwards; Andrea M Vincent; Hsinlin T Cheng; Eva L Feldman
Journal:  Pharmacol Ther       Date:  2008-06-13       Impact factor: 12.310

10.  Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis.

Authors:  Viktor R Drel; Pal Pacher; Tayyeba K Ali; Jeho Shin; Ulrich Julius; Azza B El-Remessy; Irina G Obrosova
Journal:  Int J Mol Med       Date:  2008-06       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.